Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Testing reveals lurtotecan is less active than its low-clearance formulation

Aug. 30, 2000

Vion begins additional phase I trial of intravenous TAPET

Aug. 29, 2000

Research points to existence of a third hereditary breast cancer gene

Aug. 29, 2000

Inex broadens Onco TCS clinical trial program

Aug. 28, 2000

New testosterone derivatives patented by Schering AG

Aug. 28, 2000

Phase I trial of novel anticancer treatment under way

Aug. 28, 2000

Synthetic analogues of 1alpha,25-(OH)2D3 may be useful in cancer chemoprevention

Aug. 28, 2000

Roche reports synthesis and antitumor activity of Ro-27-0574

Aug. 28, 2000

Vanadocenes induce germ cell apoptosis in mouse model of testicular cancer

Aug. 28, 2000

Selenazolidine prodrugs synthesized as potential chemopreventive agents

Aug. 25, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...